And it appears to be the case that the booster shots work against the beta and delta variants that swept the world, indicating that it may follow suit as far as the recently-identified, rapidly spreading variant of concern, omicron, goes.
A study published in The Lancet revealed that the blinded, multicentre, randomised, controlled, phase 2 trial, COV-BOOST, carried out among 2,878 people who met certain criteria and who were given a COVID-19 booster vaccine or control, indicated that the third doses are doing their job.
Several COVID-19 vaccines were used in the trial – all were administered via intramuscular injection into the upper arm. The vaccines tested were made by AstraZeneca, Novavax, Pfizer/BioNTech, Valneva, Janssen, Moderna and CureVac. All of these boosted immunity in younger and older people with varying efficacy.
